Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral meds

Novo Nordisk is off and running with its launch for oral semaglutide, a Type 2 diabetes med carrying blockbuster expectations. But the company also sees potential new uses for its oral delivery platform, and it's bolstering its manufacturing network to support its forays in that direction.